• Title/Summary/Keyword: drug-therapy

Search Result 1,321, Processing Time 0.024 seconds

Combination therapy with cilostazol, aripiprazole, and donepezil protects neuronal cells from β-amyloid neurotoxicity through synergistically enhanced SIRT1 expression

  • Heo, Hye Jin;Park, So Youn;Lee, Yi Sle;Shin, Hwa Kyoung;Hong, Ki Whan;Kim, Chi Dae
    • The Korean Journal of Physiology and Pharmacology
    • /
    • v.24 no.4
    • /
    • pp.299-310
    • /
    • 2020
  • Alzheimer's disease (AD) is a multi-faceted neurodegenerative disease. Thus, current therapeutic strategies require multitarget-drug combinations to treat or prevent the disease. At the present time, single drugs have proven to be inadequate in terms of addressing the multifactorial pathology of AD, and multitarget-directed drug design has not been successful. Based on these points of views, it is judged that combinatorial drug therapies that target several pathogenic factors may offer more attractive therapeutic options. Thus, we explored that the combination therapy with lower doses of cilostazol and aripiprazole with add-on donepezil (CAD) might have potential in the pathogenesis of AD. In the present study, we found the superior efficacies of donepezil add-on with combinatorial mixture of cilostazol plus aripiprazole in modulation of expression of AD-relevant genes: Aβ accumulation, GSK-3β, P300, acetylated tau, phosphorylated-tau levels, and activation of α-secretase/ADAM 10 through SIRT1 activation in the N2a Swe cells expressing human APP Swedish mutation (N2a Swe cells). We also assessed that CAD synergistically raised acetylcholine release and choline acetyltransferase (CHAT) expression that were declined by increased β-amyloid level in the activated N2a Swe cells. Consequently, CAD treatment synergistically increased neurite elongation and improved cell viability through activations of PI3K, BDNF, β-catenin and α7-nicotinic cholinergic receptors in neuronal cells in the presence of Aβ1-42. This work endorses the possibility for efficient treatment of AD by supporting the synergistic therapeutic potential of donepezil add-on therapy in combination with lower doses of cilostazol and aripiprazole.

Current Trend of Scalp Care Technology of Microneedle Using Fermented Soybean (대두 발효물을 이용한 마이크로니들 두피케어에 관한 최신 동향)

  • Kim, Eun-Ju;Jung, Hyun-Ki;Kim, Sung-Jun
    • Journal of the Society of Cosmetic Scientists of Korea
    • /
    • v.36 no.4
    • /
    • pp.241-251
    • /
    • 2010
  • In recent years, the number of people suffering from depression due to hair loss has been increasing. The treatment methods such as clinical pathology and vanity surgery have been developed. There are therapies and materials for hair growth promotion and hair loss prevention. But the effectiveness of such therapies and materials is not fully evaluated and some side-effects have been reported. In this study, microneedle therapy using very thin and delicate needles promotes absorption of drug. During this therapy, the microneedle makes micro holes that help absorbion of drugs into the scalp. In this study, absorbion of fermented soybean were evaluated. The ingredient has antioxidant, antiandrogen, and antithrombosis effect for alopecia. The fermented soybean is more effective for complex hair loss when used with microneedle. It is because of the microneedle's excellent drug delivery system (DDS). This therapy that increases the absorption of fermented soybean is a very useful scalp care method which prevents, treats and controls alopecia. This microneedle therapy using fermented soybean is an advanced technology for scalp care.

From Bench to Market: Preparing Human Pluripotent Stem Cells Derived Cardiomyocytes for Various Applications

  • Moon, Sung-Hwan;Bae, Daekyeong;Jung, Taek-Hee;Chung, Eun-Bin;Jeong, Young-Hoon;Park, Soon-Jung;Chung, Hyung-Min
    • International Journal of Stem Cells
    • /
    • v.10 no.1
    • /
    • pp.1-11
    • /
    • 2017
  • Human cardiomyocytes (CMs) cease to proliferate and remain terminally differentiated thereafter, when humans reach the mid-20s. Thus, any damages sustained by myocardium tissue are irreversible, and they require medical interventions to regain functionality. To date, new surgical procedures and drugs have been developed, albeit with limited success, to treat various heart diseases including myocardial infarction. Hence, there is a pressing need to develop more effective treatment methods to address the increasing mortality rate of the heart diseases. Functional CMs are not only an important in vitro cellular tool to model various types of heart diseases for drug development, but they are also a promising therapeutic agent for cell therapy. However, the limited proliferative capacity entails difficulties in acquiring functional CMs in the scale that is required for pathological studies and cell therapy development. Stem cells, human pluripotent stem cells (hPSCs) in particular, have been considered as an unlimited cellular source for providing functional CMs for various applications. Notable progress has already been made: the first clinical trials of hPSCs derived CMs (hPSC-CMs) for treating myocardial infarction was approved in 2015, and their potential use in disease modeling and drug discovery is being fully explored. This concise review gives an account of current development of differentiation, purification and maturation techniques for hPSC-CMs, and their application in cell therapy development and pharmaceutical industries will be discussed with the latest experimental evidence.

COVID-19 Drug Development

  • Kim, Seungtaek
    • Journal of Microbiology and Biotechnology
    • /
    • v.32 no.1
    • /
    • pp.1-5
    • /
    • 2022
  • Diagnostics, vaccines, and drugs are indispensable tools and control measures employed to overcome infectious diseases such as coronavirus disease 2019 (COVID-19). Diagnostic tools based on RT-PCR were developed early in the COVID-19 pandemic and were urgently required for quarantine (testing, tracing and isolation). Vaccines such as mRNA vaccines and virus-vectored vaccines were also successfully developed using new platform technologies within one year after identifying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the causative agent of COVID-19. Drug development has been conducted in various ways including drug repurposing, convalescent plasma therapy, and monoclonal antibody development. Among the above efforts, this review examines COVID-19 drug development along with the related and upcoming challenges.

Sport and exercise impact on the therapy with nanomedicine in drug delivery

  • Zhang, Bo;Jin, Hao;Duan, Xiaojing
    • Advances in nano research
    • /
    • v.13 no.3
    • /
    • pp.269-284
    • /
    • 2022
  • Nanomachines can be pretty helpful in curing diseases. Nanomototors, thanks to their self-propelled feature, are one of the best structures to be utilized as drug delivery devices. These devices have been employed in biomedical application as they can improve the efficiency of drug delivery. In this study stability of a designed nanomotor in the bloodstream is investigated when the physical activities have been done considering the physical activities. Sports training, as well as exercise enhance the bloodstream, and this factor can significantly impact the drug-delivery quality. The mathematical simulation of nanomotor movement in the condition of the sports is done based on the mechanical sciences, and the impact of various essential parameters is discussed in detail.

The Trend of Organic Based Nanoparticles in the Treatment of Diabetes and Its Perspectives

  • Vijayakumar Natesan;Sung-Jin Kim
    • Biomolecules & Therapeutics
    • /
    • v.31 no.1
    • /
    • pp.16-26
    • /
    • 2023
  • Diabetes is an untreatable metabolic disorder characterized by alteration in blood sugar homeostasis, with submucosal insulin therapy being the primary treatment option. This route of drug administration is attributed to low patient comfort due to the risk of pain, distress, and local inflammation/infections. Nanoparticles have indeed been suggested as insulin carriers to allow the drug to be administered via less invasive routes other than injection, such as orally or nasally. The organic-based nanoparticles can be derived from various organic materials (for instance, polysaccharides, lipids, and so on) and thus are prevalently used to enhance the physical and chemical consistency of loaded bioactive compounds (drug) and thus their bioavailability. This review presents various forms of organic nanoparticles (for example, chitosan, dextron, gums, nanoemulsion, alginate, and so on) for enhanced hypoglycemic drug delivery relative to traditional therapies.

Safety evaluation of biological products in Korea

  • Han, Eui-Sik
    • Proceedings of the Korean Society of Toxicology Conference
    • /
    • 2003.10b
    • /
    • pp.89-90
    • /
    • 2003
  • Biological products are composed of vaccines, antitoxin, blood products, DNA recombinant protein drugs, monoclonal antibody, cell therapy and gene therapy. Biological products are divided into traditional (i.e. recombinant proteins and monoclonal antibodies) and novel biological products (gene and cell therapy) and will require a similar re-evaluation of the approaches taken during each development program.(omitted)

  • PDF

A Case Study on Leukopenia Patients Using Ortho-Cellular Nutrition Therapy (OCNT) (세포교정영양요법(OCNT)을 이용한 백혈구 감소증 사례 연구)

  • Jeonghwa Baek
    • CELLMED
    • /
    • v.13 no.11
    • /
    • pp.38.1-38.9
    • /
    • 2023
  • Objective: A case report on the Leukopenia Patients Using Ortho-Cellular Nutrition Therapy (OCNT) Methods: A Korean female in her 50s suffering from the rare side effect of leukopenia after taking athlete's foot medicine (Terbinafine HCl) Results: The results revealed that the white blood cell count, which had dropped before the OCNT, had improved to a normal level. Conclusion: The application of the OCNT can help change health-related figures in patients with relevant problems.

Roles of Valproic Acid in Improving Radiation Therapy for Glioblastoma: a Review of Literature Focusing on Clinical Evidence

  • Ochiai, Satoru;Nomoto, Yoshihito;Yamashita, Yasufumi;Watanabe, Yui;Toyomasu, Yutaka;Kawamura, Tomoko;Takada, Akinori;Ii, Noriko;Kobayashi, Shigeki;Sakuma, Hajime
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.17 no.2
    • /
    • pp.463-466
    • /
    • 2016
  • Glioblastoma (GBM) is the most common and aggressive type of primary brain neoplasm. The current standard therapy for GBM consists of maximal surgical resection within safe limits, followed by radiation therapy (RT) and chemotherapy with temozolomide. Despite advances in treatment, the prognosis of GBM remains poor. Epileptic seizure is one of the most common symptoms in patients with GBM. Valproic acid (VPA), a histone deacetylase inhibitor, is often used as an anti-epileptic drug in patients with brain neoplasms due to its effectiveness and low toxicity profile. Several in vivo and in vitro studies have indicated that VPA has radiosensitizing effects for gliomas and radioprotective influence on normal brain tissue or hippocampal neurons. The results of several retrospective studies have also indicated potential benefit to improve survival of patients with GBM. Moreover, the promising treatment results of a phase 2 trial of concurrent radiation therapy, temozolomide, and VPA for patients with GBM have been recently reported. The use of VPA in patients with GBM has thus recently receiving more attention. In this article, we review the role of VPA in radiation therapy for GBM, focusing on the clinical evidence.

Utilization of Preventive Therapy in Korean Migraine Patients

  • Kim, Yewon;Park, Susin;Kim, Eonjeong;Je, Nam Kyung
    • Korean Journal of Clinical Pharmacy
    • /
    • v.31 no.1
    • /
    • pp.35-43
    • /
    • 2021
  • Background: Migraine is a common neurological disorder that affects the quality of life and causes several health problems. Preventive migraine treatment can reduce migraine frequency, headache severity, and health care costs. This study aimed to estimate the utilization of migraine preventive therapy and associated factors in eligible patients. Methods: We studied 534 patients with migraine who were eligible for migraine preventive therapy using 2017 National Patient Sample (NPS) data from the Health Insurance Review and Assessment Service (HIRA). We estimated the migraine days by calculating the monthly average number of defined daily dose (DDD) of migraine-specific acute drug. Patients with a monthly average number of DDD of 4 or more were considered as subjects for preventive treatment. Chi-square test and multiple logistic regression analysis were used to determine the association between the preventive therapy and the influencing variables. Results: Less than half of the eligible patients for prophylaxis (n=234, 43.8%) were prescribed preventive therapy. Multiple logistic regression results show that migraine preventive therapy was influenced by age, the type of migraine, and some comorbidities. Patients over the age of 50 tend to receive less prophylactic treatment than under the age of 40. On the other hand, migraine patients with epilepsy or depression were more likely to receive preventive therapy. Sumatriptan was the most preferred medication for acute treatment, and propranolol was the most commonly prescribed drug for prevention. Conclusions: More than half of the patients who were candidates for migraine prophylaxis were not receiving suitable preventive treatment. Positive factors affecting the use of migraine prevention were the presence of comorbidities such as epilepsy and depression.